Dimensional Fund Advisors LP Decreases Stake in Amedisys, Inc. (NASDAQ:AMED)

Dimensional Fund Advisors LP cut its holdings in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 1.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 503,391 shares of the health services provider's stock after selling 5,894 shares during the period. Dimensional Fund Advisors LP owned about 1.54% of Amedisys worth $45,703,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Blue Trust Inc. grew its stake in Amedisys by 55.1% during the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock valued at $34,000 after purchasing an additional 124 shares in the last quarter. HBW Advisory Services LLC purchased a new position in shares of Amedisys during the 4th quarter valued at approximately $38,000. Versant Capital Management Inc grew its position in shares of Amedisys by 68.5% during the fourth quarter. Versant Capital Management Inc now owns 450 shares of the health services provider's stock worth $41,000 after buying an additional 183 shares in the last quarter. Vestcor Inc bought a new stake in shares of Amedisys in the fourth quarter worth $73,000. Finally, Venturi Wealth Management LLC boosted its stake in Amedisys by 397.4% during the 4th quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider's stock valued at $89,000 after acquiring an additional 779 shares during the last quarter. 94.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Royal Bank of Canada restated an "outperform" rating and issued a $100.00 target price on shares of Amedisys in a research note on Wednesday, April 16th. Stephens reaffirmed an "equal weight" rating and set a $101.00 target price on shares of Amedisys in a report on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $100.75.

Amedisys Price Performance

AMED opened at $96.00 on Friday. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. The company's 50-day moving average price is $92.58 and its 200 day moving average price is $91.74. Amedisys, Inc. has a fifty-two week low of $82.15 and a fifty-two week high of $98.95. The firm has a market cap of $3.15 billion, a price-to-earnings ratio of 38.10, a price-to-earnings-growth ratio of 1.78 and a beta of 0.96.

Amedisys (NASDAQ:AMED - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.12. The business had revenue of $594.78 million for the quarter, compared to the consensus estimate of $597.43 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The business's revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the business posted $1.03 EPS. As a group, sell-side analysts expect that Amedisys, Inc. will post 4.4 earnings per share for the current year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.